TIDMVENN

RNS Number : 3415L

Venn Life Sciences Holdings PLC

21 December 2018

21 December 2018

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Director/PDMR Dealings

Venn Life Sciences ("Venn") an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations announces that Michael Ryan, Senior Independent Director, has sold 138,672 ordinary shares in Venn at a price of 1.9p per share, in order to crystalise certain capital tax losses. Following this sale, Mr Ryan remains interested in 134,586 ordinary shares in the Company.

Further information is disclosed below pursuant to Article 19(3) of the Market Abuse Regulation.

 
 1      Details of the person discharging managerial responsibilities 
         / person closely associated 
 a)     Name                                Michael Ryan 
       ----------------------------------  ---------------------------------------------- 
 2      Reason for the notification 
       ---------------------------------------------------------------------------------- 
 a)     Position/status                     Senior Independent Director 
       ----------------------------------  ---------------------------------------------- 
 b)     Initial notification                Initial Notification 
         /Amendment 
       ----------------------------------  ---------------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ---------------------------------------------------------------------------------- 
 a)     Name                                Venn Life Science Holdings PLC 
 
  b)     LEI code                            213800VT5KBM7JLIV118 
       ----------------------------------  ---------------------------------------------- 
 4      Details of the transaction(s): section to be repeated for (i) 
         each type of instrument; (ii) each type of transaction; (iii) 
         each date; and (iv) each place where transactions have been 
         conducted 
       ---------------------------------------------------------------------------------- 
 a)     Description of the                  Ordinary Shares of nominal value of 0.1 
         financial instrument,               pence each 
         type of instrument 
 
        Identification code                 ISIN GB00B9275X97 
 
 b)     Nature of the transaction           Sale of ordinary shares 
       ----------------------------------  ---------------------------------------------- 
 c)     Price(s) and volume(s) 
                                            -------------------------  ---------------- 
                                             Price(s)                   Volume(s) 
                                            -------------------------  ---------------- 
    1.9p per share                                                      138,672 
   ------------------------------------------------------------------  ---------------- 
 
 d)     Aggregated information 
 
  - Aggregated volume                 N/A - single transaction 
 
  - Price 
 
 e)     Date of the transaction             21 December 2018 
       ----------------------------------  ---------------------------------------------- 
 f)     Place of the transaction            London Stock Exchange (AIM) 
       ----------------------------------  ----------------------------------------------

Enquiries:

 
 
  Venn Life Sciences Holdings Plc 
 
Tony Richardson, Chief Executive Officer                       Tel: +353 1 5499341 
 
Cenkos (Nominated Advisor and Co-Broker)                   Tel: +44(0)20 7397 8900 
 Mark Connelly/Steve Cox (Corporate Finance) 
 
Davy (ESM Adviser and Co-Broker) 
Fergal Meegan / Matthew de Vere White (Corporate              Tel: +353 1 679 6363 
 Finance)

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.vennlifesciences.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHLLFFRFRLLFIT

(END) Dow Jones Newswires

December 21, 2018 11:29 ET (16:29 GMT)

Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Hvivo.
Hvivo (LSE:HVO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Hvivo.